Dogwood Therapeutics CMO Roger Gendreau Receives 82,500-Share Grant

What Happened

• Roger Gendreau, Chief Medical Officer of Dogwood Therapeutics (DWTX), received a derivative award on 2026-03-05 for 82,500 shares. The filing reports an acquisition price of $0.00 (derivative award/stock option), so no cash was paid at grant and no immediate sale or exercise was reported.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 6, 2026 (timely).
• Reported transaction: Award/Grant (derivative) of 82,500 shares; acquisition price shown as $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The stock option vests one-third on March 5, 2027 and then 1/24th monthly thereafter.
• No 10b5-1 plan, tax-withholding sell, or immediate cashless exercise/sale was reported.

Context

• This was a stock-option grant (a common compensation event) rather than an open-market purchase or sale. Because the award vests over time, it does not represent an immediate investment or liquidity action and should be viewed as compensation rather than a direct buy/sell signal.